- Record: found
- Abstract: not found
- Article: not found
Raising the safety bar--the FDA's coxib meeting.
2005-03-31
Advertising as Topic, legislation & jurisprudence, Advisory Committees, Anti-Inflammatory Agents, Non-Steroidal, adverse effects, therapeutic use, Arthritis, drug therapy, Cardiovascular Diseases, chemically induced, Clinical Trials as Topic, Cyclooxygenase Inhibitors, Drug Approval, Drug Industry, Drug Labeling, Humans, Isoxazoles, Lactones, Product Surveillance, Postmarketing, Pyrazoles, Sulfonamides, Sulfones, United States, United States Food and Drug Administration
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Author and article information
Advertising as Topic,legislation & jurisprudence,Advisory Committees,Anti-Inflammatory Agents, Non-Steroidal,adverse effects,therapeutic use,Arthritis,drug therapy,Cardiovascular Diseases,chemically induced,Clinical Trials as Topic,Cyclooxygenase Inhibitors,Drug Approval,Drug Industry,Drug Labeling,Humans,Isoxazoles,Lactones,Product Surveillance, Postmarketing,Pyrazoles,Sulfonamides,Sulfones,United States,United States Food and Drug Administration
Advertising as Topic, legislation & jurisprudence, Advisory Committees, Anti-Inflammatory Agents, Non-Steroidal, adverse effects, therapeutic use, Arthritis, drug therapy, Cardiovascular Diseases, chemically induced, Clinical Trials as Topic, Cyclooxygenase Inhibitors, Drug Approval, Drug Industry, Drug Labeling, Humans, Isoxazoles, Lactones, Product Surveillance, Postmarketing, Pyrazoles, Sulfonamides, Sulfones, United States, United States Food and Drug Administration